30 closest matches · ranked by relevance
Anaplastic Large Cell Lymphoma, ALK-Positive · Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma · Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Primary: Occurrence of Grade 3+ Non-hematologic Adverse Events — 80.6; 87.9 Percentage of patients
Lymphoma
Primary: Objective Response Rate (ORR) — 64 percentage of participants
Lymphoma
Primary: Event-free Survival (EFS) — 74; 79 percentage of participants
Lymphoma, Large-Cell, Anaplastic · Lymphoma, Non-Hodgkin
Primary: Objective Response Rate by Independent Review Group — 86 percent of participants
Recurrent Childhood Anaplastic Large Cell Lymphoma · Recurrent Malignant Solid Neoplasm · Recurrent Neuroblastoma
Primary: Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib — 280 mg/m²/dose BID
Relapsed Peripheral T-Cell Lymphoma · Refractory Peripheral T-Cell Lymphoma
Primary: Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment — 33; 45 percentage of participants — p=0.038
Anaplastic Large Cell Lymphoma · Recurrent Adult Hodgkin Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Number of Patients With Response — 0; 2 participants
Non-Small-Cell Lung Carcinoma
Primary: Number of Participants Classified According to Treatments Received for Anaplastic Lymphoma Kinase Positive-non-Small Cell Lung Cancer (ALK + NSCLC) in Sequence — 103; 8…
Adult Nasal Type Extranodal NK/T-Cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-Cell Lymphoma
Primary: Objective Response Rate (Complete Responses (CR) + Partial Responses (PR)) — 2; 7; 28 participants
Lymphoma, Large-Cell, Anaplastic · Enteropathy-Associated T-Cell Lymphoma · Lymphoma, Large B-Cell, Diffuse
Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…
T Cell Lymphoma
Primary: Overall Response Rate — 5 participants
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Hodgkin Disease · Lymphoma, Large-Cell, Anaplastic
Primary: Overall Response Rate (ORR) — 70.0; 66.7 percentage of participants
Lymphoma, T-Cell · Lymphoma, Extranodal NK-T-Cell
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg
Lymphoma
Primary: Dose Limiting Toxicity (DLT) — 0; 1; 1 Participants
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate — 54.1; 40.5 Percentage of participants
Peripheral T Cell Lymphoma
Primary: Efficacy: Complete Response Rate — 11 Participants — p=.1
Hodgkin Lymphoma · Anaplastic Large-cell Lymphoma
Primary: Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, Predose — NA; NA; NA; NA ng/mL
Carcinoma, Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS) — 7.7; 3.0 months — p=<0.0001
Peripheral T Cell Lymphoma
Primary: Overall Response Rate (ORR) at Four Months (LYRIC Criteria) — 2; 0; 1 Participants
Tumors Characterized by Genetic Abnormalities of ALK
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
Primary: Number of Participants Who Had One or More Adverse Events (AE) and Serious Adverse Events (SAE) — 238; 97 Participants
Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepatosplenic T-cell Lymphoma
Primary: Overall Response (OR) Rate — 0.07 Proportion of participants
Non-squamous Non-small-cell Lung Cancer · Anlotinib
Primary: the Maximum Tolerated Dose (MTD) — 10 mg
Childhood Solid Neoplasm · Recurrent Childhood Anaplastic Large Cell Lymphoma · Recurrent Neuroblastoma
Primary: Maximum Tolerated Dose (MTD) of Crizotinib — 215 mg/m^2
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) — 16.6; 8.1 Months — p=<0.001
Adult Diffuse Large Cell Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma · Stage IV Adult Diffuse Large Cell Lymphoma
Primary: Objective Tumor Response — 0 participants
Peripheral T Cell Lymphoma · Transformed Mycosis Fungoides
Primary: Overall Response Rate Assessed by Independent Review Committee Based on PET-CT — 32.4 percentage — p=0.051
NSCLC (Non-small Cell Lung Cancer)
Primary: Progression-Free Survival (PFS) Based on IRR by Treatment Arm — 11.1; 6.8 Months — p=<0.0001